MariMed Inc. (OTCMKTS:MRMD – Get Free Report) saw a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 64,138 shares, an increase of 1,827.8% from the May 14th total of 3,327 shares. Based on an average trading volume of 1,254,952 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the stock are short sold.
MariMed Stock Performance
OTCMKTS:MRMD opened at $0.07 on Thursday. The company has a quick ratio of 0.34, a current ratio of 0.95 and a debt-to-equity ratio of 1.67. MariMed has a fifty-two week low of $0.06 and a fifty-two week high of $0.23. The stock has a market cap of $28.74 million, a PE ratio of -2.40 and a beta of 1.30. The firm’s fifty day simple moving average is $0.08 and its 200-day simple moving average is $0.08.
MariMed (OTCMKTS:MRMD – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). MariMed had a negative net margin of 7.82% and a negative return on equity of 5.00%. The firm had revenue of $39.48 million during the quarter, compared to analysts’ expectations of $38.75 million. Analysts expect that MariMed will post -0.04 earnings per share for the current fiscal year.
MariMed Company Profile
MariMed Inc is a multi?state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult?use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.
The company’s product portfolio includes branded flower, pre?rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.
Featured Articles
- Five stocks we like better than MariMed
- Casey’s Is Looking Like a Hot Buy as Growth, Buybacks, and Guidance Align
- The “Duck Stock” Keeps Quietly Making Money for Shareholders
- As Shares Fall, Analyst Are Boosting their Broadcom Price Targets
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.
